2018
DOI: 10.1053/j.seminoncol.2018.07.001
|View full text |Cite
|
Sign up to set email alerts
|

Epidemiologic trends in neuroendocrine tumors: An examination of incidence rates and survival of specific patient subgroups over the past 20 years

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3

Citation Types

4
48
1
1

Year Published

2019
2019
2024
2024

Publication Types

Select...
5
1

Relationship

0
6

Authors

Journals

citations
Cited by 65 publications
(54 citation statements)
references
References 24 publications
4
48
1
1
Order By: Relevance
“…The baseline characteristics of mNET patients were consistent with those previously reported; the majority of patients had a primary tumor in the small intestine or pancreas, a nonfunctioning tumor, and liver metastases [2]. Interestingly, although no significant difference was found herein when stratifying by age, it has recently been reported using results from the SEER database that the frequency of distant metastatic disease at diagnosis decreases in function of younger age (from 34% at age > 70 years to 11% at age ≤20 years), as does the frequency of grade 3 tumors (from 41% at age > 70 years to 16% at age ≤20 years) [2]. However, it should be noted that the SEER database also included poorly differentiated neuroendocrine carcinoma in the grade 3 category [2], which was not the case herein.…”
Section: Discussionsupporting
confidence: 85%
See 4 more Smart Citations
“…The baseline characteristics of mNET patients were consistent with those previously reported; the majority of patients had a primary tumor in the small intestine or pancreas, a nonfunctioning tumor, and liver metastases [2]. Interestingly, although no significant difference was found herein when stratifying by age, it has recently been reported using results from the SEER database that the frequency of distant metastatic disease at diagnosis decreases in function of younger age (from 34% at age > 70 years to 11% at age ≤20 years), as does the frequency of grade 3 tumors (from 41% at age > 70 years to 16% at age ≤20 years) [2]. However, it should be noted that the SEER database also included poorly differentiated neuroendocrine carcinoma in the grade 3 category [2], which was not the case herein.…”
Section: Discussionsupporting
confidence: 85%
“…Interestingly, although no significant difference was found herein when stratifying by age, it has recently been reported using results from the SEER database that the frequency of distant metastatic disease at diagnosis decreases in function of younger age (from 34% at age > 70 years to 11% at age ≤20 years), as does the frequency of grade 3 tumors (from 41% at age > 70 years to 16% at age ≤20 years) [2]. However, it should be noted that the SEER database also included poorly differentiated neuroendocrine carcinoma in the grade 3 category [2], which was not the case herein. To the best of our knowledge, the present study is the first to report that elderly mNET patients were undertreated compared to patients < 70 years old, which could, at least in part, explain the poorer prognosis reported both herein and elsewhere for NET [2,4].…”
Section: Discussioncontrasting
confidence: 64%
See 3 more Smart Citations